Importance There is increasing interest in the effect of cardiovascular disease on cancer
survivors. However, there are limited contemporary population-based data on the risk of …

Background The cardiovascular risk of angiogenesis inhibitors is not well-quantified. We
hypothesized that, compared to direct vascular endothelial growth factor (VEGF) inhibitors (anti-…

Purpose Most women diagnosed with breast cancer are younger than 65 years of age.
Population-based studies on cancer therapy–related cardiotoxicity have focused on older women…

Aims This study aimed to review the performance of machine learning (ML) methods compared
with conventional statistical models (CSMs) for predicting readmission and mortality in …

Background Sodium glucose cotransporter-2 inhibitors (SGLT2is) are hypothesized to
reduce the risk of anthracycline-associated cardiotoxicity. Objectives This study sought to …

Background: Ignoring competing risks in time-to-event analyses can lead to biased risk
estimates, particularly for elderly patients with multimorbidity. We aimed to demonstrate the …

BACKGROUND: The array of outcomes according to longitudinal furosemide doses in heart
failure (HF) have not been evaluated. We examined the relationship of dynamic furosemide …

Background Statins are hypothesized to reduce the risk of cardiotoxicity associated with
anthracyclines and trastuzumab. Our aim was to study the association of statin exposure with …

PURPOSE Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL). It increases
the risk of atrial fibrillation (AF) and bleeding and there are concerns about heart failure (HF) …

Background There remains a paucity of real-world observational evidence comparing
percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients …